Valuation: Celsion Corporation

Market Cap 62.85L 56.15L 52.39L 47.59L 89.62L 61Cr 90.29L 6.3Cr 2.46Cr 31Cr 2.36Cr 2.31Cr 99Cr P/E 2026 *
-0.47x
P/E 2027 * -0.6x
Enterprise Value 62.85L 56.15L 52.39L 47.59L 89.62L 61Cr 90.29L 6.3Cr 2.46Cr 31Cr 2.36Cr 2.31Cr 99Cr EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.27%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Celsion Corporation

Manager TitleAgeSince
Chief Executive Officer 56 13/05/2024
Director of Finance/CFO 53 01/07/2026
Chief Tech/Sci/R&D Officer 73 18/02/2025
Director TitleAgeSince
Chairman 75 07/10/2014
Director/Board Member 75 08/07/2011
Director/Board Member 76 15/12/2015
Change 5-day change 1-year change 3-year change Capi.($)
+4.16%+4.16%+49.37%+94.17% 7.47TCr
+0.46%-1.16%+23.36%+79.34% 5.88TCr
+0.17%-1.16%+3.59%+34.55% 4.84TCr
+0.50%-2.14%+331.33%+688.65% 4.28TCr
-0.72%-3.99%+28.50%+29.35% 4.28TCr
+0.34%-0.52%+6.56%+110.67% 4.12TCr
-0.11%+1.96%+9.19%+52.66% 3.11TCr
-2.07%+1.16%+35.00%+26.28% 3.03TCr
-0.50%-3.10%-10.19%-12.86% 2.4TCr
Average +0.06%-0.25%+52.97%+122.53% 4.38TCr
Weighted average by Cap. +0.53%-0.54%+55.85%+128.90%

Financials

2026 *2027 *
Net sales - -
Net income -1.45Cr -1.29Cr -1.21Cr -1.1Cr -2.06Cr -139.95Cr -2.08Cr -14Cr -5.66Cr -71Cr -5.43Cr -5.31Cr -228.81Cr -1.86Cr -1.66Cr -1.55Cr -1.4Cr -2.65Cr -179.47Cr -2.67Cr -19Cr -7.26Cr -91Cr -6.96Cr -6.81Cr -293.41Cr
Net Debt - -
Logo Celsion Corporation
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases, constituting a differentiating approach from conventional therapies. The Company is developing its non-viral DNA technology across its modalities. The first modality, TheraPlas, is developed for the gene-based delivery of cytokines and other therapeutic proteins in the treatment of solid tumors. The second modality, PlaCCine, is developed for the gene delivery of viral antigens that can elicit a strong immunological response. The Company’s lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer that has completed Phase 2 development. IMNN-001 works by instructing the body to produce safe and durable levels of powerful cancer-fighting molecules, such as interleukin-12 and interferon gamma, at the tumor site.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Ratings Surperformance© - Celsion Corporation